- Risankizumab Induction Therapy in Patients With Moderate-to-Severe Crohn's Disease with Intolerance or Inadequate Response to Conventional and/or Biologic Therapy: Results from the Phase 3 ADVANCE Study(2021)
Auteurs: Peter Bossuyt
Pagina's: E28 - E28
- Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus(2021)
Auteurs: Peter Bossuyt
- Risk of Late Postoperative Recurrence of Crohn's Disease in Patients in Endoscopic Remission After Ileocecal Resection, Over 10 Years at Multiple Centers(2021)
Auteurs: Peter Bossuyt
Pagina's: 1218 - +
- International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases(2021)
Auteurs: Peter Bossuyt
Pagina's: 451 - 460
- QUALITY IMPROVEMENT BY SEMI-AUTOMATED BENCHMARKING OF A CORE OUTCOME INDICATOR SET IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRIC FEASIBILITY STUDY(2021)
Auteurs: Peter Bossuyt
Pagina's: S356 - S356
- EFFICACY, SAFETY AND MUCOSAL HEALING OF EARLY VERSUS LATE USE OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY(2021)
Auteurs: Séverine Vermeire, Marc Ferrante, Peter Bossuyt
Pagina's: S91 - S92
- Tofacitinib and Subacute Pneumonitis: Don't Hold Your Breath(2021)
Auteurs: Bram Verstockt, Peter Bossuyt
Pagina's: 692 - 693
- Variability in the Distribution of Histological Disease Activity in the Colon of Patients with Ulcerative Colitis(2021)
Auteurs: Peter Bossuyt, Raf Bisschops, Séverine Vermeire, Gert De Hertogh
Pagina's: 603 - 608
- Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn's Disease(2021)
Auteurs: Peter Bossuyt, Erwin Dreesen, Séverine Vermeire
Pagina's: 947 - +
- Health Literacy and Quality of Life in Young Adults From The Belgian Crohn's Disease Registry Compared to Type 1 Diabetes Mellitus(2021)
Auteurs: Lucas Wauters, An Outtier, Peter Bossuyt, Marc Ferrante, Ilse Hoffman, Bram Verstockt, Séverine Vermeire